1. Home
  2. GIFT vs NRSN Comparison

GIFT vs NRSN Comparison

Compare GIFT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RDE Inc. Common Stock

GIFT

RDE Inc. Common Stock

HOLD

Current Price

$1.08

Market Cap

33.6M

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.90

Market Cap

29.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIFT
NRSN
Founded
1999
2017
Country
United States
Israel
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.6M
29.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
GIFT
NRSN
Price
$1.08
$0.90
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$4.00
$14.00
AVG Volume (30 Days)
26.5K
433.4K
Earning Date
11-10-2025
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$86,142,442.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.20
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.81
52 Week High
$2.38
$2.60

Technical Indicators

Market Signals
Indicator
GIFT
NRSN
Relative Strength Index (RSI) 47.77 36.61
Support Level $1.07 $1.07
Resistance Level $1.14 $1.24
Average True Range (ATR) 0.05 0.12
MACD -0.00 -0.02
Stochastic Oscillator 27.78 1.53

Price Performance

Historical Comparison
GIFT
NRSN

About GIFT RDE Inc. Common Stock

Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: